The “China Pharmaceutical Contract Manufacturing Services Market, 2020-2030
Key Inclusions
§ A review of the current market landscape of companiesoffering pharmaceutical contract manufacturing services in China, along withinformation on year of establishment, company size, location of headquarters,type of product (active pharmaceutical ingredients (APIs), intermediates andfinished dosage formulations (FDFs)), type of FDFs, type of packaging andnumber of manufacturing facilities.
§ A detailed landscape of the pharmaceutical manufacturingfacilities in China, including an analysis based on location of thesefacilities, highlighting key manufacturing hubs.
§ A brief discussion of various guidelines laid down byregulatory authorities in China for the manufacturing of pharmaceuticals. Italso provides information on various challenges, related to regulatoryscrutiny, faced by pharmaceutical manufacturers in China.
§ Elaborate profiles of key players that offer a diverserange of capabilities for the manufacturing of pharmaceutical products inChina. Each profile includes an overview of the company, information related toits pharmaceutical manufacturing service portfolio, details related to itsmanufacturing facilities, recent developments, and an informed future outlook.
§ A review of the pharmaceutical manufacturing relatedinitiatives of the top 10 big pharma players (shortlisted from the topcompanies of 2019 by revenues), featuring a [A] analysis by investments made,with detailed information on investments related to R&D centers andmanufacturing facilities in established and emerging regions of China, [B]Harvey ball framework, presenting a summary of all initiatives
§ A case study of the key recent developments (includingpartnerships and acquisitions) pertaining to the manufacturing ofpharmaceutical drugs, during 2014-2020 (till February), based on severalparameters, such as year of partnership, type of partnership and geography.
§ A detailed capacity analysis based on the individualreactor capacities of various industry stakeholders, taking into considerationparameters, such as company size (small-sized, mid-sized, large and verylarge), and location of the manufacturing facility (Eastern China, SouthernChina and Northern China).
§ A discussion on industry affiliated trends, key drivers andchallenges, under a SWOT framework, which are likely to impact the evolution ofthis field. It also includes a Harvey ball analysis, highlighting the relativeimpact of each SWOT parameter on industry dynamics.
§ A case study comparing the key characteristics of largemolecule and small molecule drugs, along with details on the various stepsinvolved in their respective manufacturing processes.
The report also features thelikely distribution of the current and forecasted opportunity across importantmarket segments, mentioned below:
§ Key GeographicalRegions
- Eastern China
- Southern China
- Northern China
§ Type of Product
- Active Pharmaceutical Ingredients (APIs)
- Drug Products
§ Type of Drug Product
- Solid
- Liquid / Semi-Solid
- Injectable
- Others
§ Scale of Operation
- Clinical
- Commercial
§ Company Size
- Small
- Mid-Sized
- Large / Very Large
To request samplepages, please visit this link
Key QuestionsAnswered
§ Who are the leading China-based pharmaceutical CMOs engagedin the production of APIs, intermediates and FDFs?
§ What are the key manufacturing hubs within China (in termsof number of manufacturing facilities)?
§ What is the current installed capacity for manufacturing ofpharmaceuticals, in China?
§ What are the major market trends and driving factors thatare likely to impact the growth of the pharmaceutical manufacturing market inChina?
§ What is the likely short-term and long-term impact of theCOVID-19 pandemic on the pharmaceutical contract manufacturing industry inChina?
§ What kind of initiatives are being undertaken by bigpharmaceutical players for pharmaceutical manufacturing in China?
§ How is the current and future market opportunity likely tobe distributed across key market segments?
You may also be interested in the followingtitles:
1. ChinaBiopharmaceutical Contract Manufacturing Market, 2020 – 2030
2. HPAPI and CytotoxicDrugs Manufacturing Market (3rd Edition), 2020-2030
3. Novel coronavirus(COVID-19): Preventive Vaccines, Therapeutics and Diagnostics in Development
Contact Us
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
